KR20210104173A - Hif 하이드록실라제 억제자의 약학적 제형 - Google Patents

Hif 하이드록실라제 억제자의 약학적 제형 Download PDF

Info

Publication number
KR20210104173A
KR20210104173A KR1020217025795A KR20217025795A KR20210104173A KR 20210104173 A KR20210104173 A KR 20210104173A KR 1020217025795 A KR1020217025795 A KR 1020217025795A KR 20217025795 A KR20217025795 A KR 20217025795A KR 20210104173 A KR20210104173 A KR 20210104173A
Authority
KR
South Korea
Prior art keywords
capsule
photostabilizer
iron oxide
weight
titanium dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217025795A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 콘카
리 알렌 플리핀
스코트 데이비드 리
클라우디아 윗쉬
리 로버트 라이트
Original Assignee
피브로겐, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210104173(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피브로겐, 인크. filed Critical 피브로겐, 인크.
Priority to KR1020227041268A priority Critical patent/KR20220164069A/ko
Publication of KR20210104173A publication Critical patent/KR20210104173A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217025795A 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형 Ceased KR20210104173A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227041268A KR20220164069A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
US61/831,909 2013-06-06
KR1020157034392A KR102291860B1 (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157034392A Division KR102291860B1 (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041268A Division KR20220164069A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Publications (1)

Publication Number Publication Date
KR20210104173A true KR20210104173A (ko) 2021-08-24

Family

ID=51063834

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217025795A Ceased KR20210104173A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
KR1020157034392A Active KR102291860B1 (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
KR1020227041268A Ceased KR20220164069A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157034392A Active KR102291860B1 (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형
KR1020227041268A Ceased KR20220164069A (ko) 2013-06-06 2014-06-05 Hif 하이드록실라제 억제자의 약학적 제형

Country Status (24)

Country Link
US (3) US20160120859A1 (https=)
EP (2) EP3708154A1 (https=)
JP (4) JP6604941B2 (https=)
KR (3) KR20210104173A (https=)
CN (5) CN105377242A (https=)
AU (1) AU2014274890B2 (https=)
CA (1) CA2914049C (https=)
CY (1) CY1122951T1 (https=)
DK (1) DK3003284T3 (https=)
ES (1) ES2786924T3 (https=)
HR (1) HRP20200615T1 (https=)
HU (1) HUE049623T2 (https=)
IL (3) IL296484B2 (https=)
LT (1) LT3003284T (https=)
ME (1) ME03777B (https=)
MX (3) MX2015016536A (https=)
PL (1) PL3003284T3 (https=)
PT (1) PT3003284T (https=)
RS (1) RS60464B1 (https=)
SG (1) SG11201509764RA (https=)
SI (1) SI3003284T1 (https=)
SM (1) SMT202000190T1 (https=)
WO (1) WO2014197660A1 (https=)
ZA (1) ZA201508712B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
KR20210130849A (ko) 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
US11192860B2 (en) 2017-09-04 2021-12-07 Sandoz Ag Co-crystal of an orally available HIF prolyl hydroxylase inhibitor
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
WO2021186356A1 (en) * 2020-03-17 2021-09-23 Cadila Healthcare Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN116832005A (zh) * 2022-03-23 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 一种罗沙司他胶囊
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
EP1574215B1 (en) 2002-12-16 2015-07-15 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
KR101194123B1 (ko) 2004-03-16 2012-10-24 아사히 가세이 파마 가부시키가이샤 패수딜 함유 제제 및 그 안정성을 개선하는 방법
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
PT1944029E (pt) 2005-10-31 2012-02-09 Nissan Chemical Ind Ltd Preparação farmacêutica com excelente fotoestabilidade
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP2476669A1 (en) 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
DE602006013781D1 (de) * 2006-02-09 2010-06-02 Teva Pharma Stabile pharmazeutische Zubereitungen von Montelukast-Natrium
US20070259960A1 (en) 2006-02-16 2007-11-08 Fibrogen, Inc. Compounds and methods for treatment of stroke
CN103497184A (zh) 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
BRPI0818323A2 (pt) 2007-10-12 2017-05-16 Astrazeneca Ab composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
CN101917996A (zh) 2007-11-02 2010-12-15 法布罗根股份有限公司 降低血压的方法
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2231157A1 (en) 2007-12-06 2010-09-29 Fibrogen, Inc. Methods for increasing endothelial progentior cells
WO2009075826A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
CN106344533A (zh) 2009-01-29 2017-01-25 大日本住友制药株式会社 具有内核的口腔崩解片剂
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
WO2012097329A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
AU2013229922B2 (en) 2012-03-09 2017-09-28 Kyntra Bio, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
KR20210130849A (ko) 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
CA2899024C (en) 2013-01-24 2022-01-04 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형

Also Published As

Publication number Publication date
BR112015029693A2 (pt) 2017-07-25
DK3003284T3 (da) 2020-03-30
CN105377242A (zh) 2016-03-02
KR20160018514A (ko) 2016-02-17
EP3003284B1 (en) 2020-02-12
IL242759B2 (en) 2023-05-01
US20220054474A1 (en) 2022-02-24
IL296484A (en) 2022-11-01
US20160120859A1 (en) 2016-05-05
CN111728952A (zh) 2020-10-02
ME03777B (me) 2021-04-20
WO2014197660A1 (en) 2014-12-11
ES2786924T3 (es) 2020-10-14
SMT202000190T1 (it) 2020-05-08
CN111728951A (zh) 2020-10-02
JP2021100971A (ja) 2021-07-08
IL296484B1 (en) 2024-11-01
IL242759A (https=) 2015-12-31
RU2681304C2 (ru) 2019-03-06
SI3003284T1 (sl) 2020-08-31
SG11201509764RA (en) 2015-12-30
MX2020003096A (es) 2020-08-17
HK1222550A1 (en) 2017-07-07
HRP20200615T1 (hr) 2020-07-10
BR112015029693A8 (pt) 2019-12-24
JP2023068197A (ja) 2023-05-16
ZA201508712B (en) 2020-07-29
JP6861758B2 (ja) 2021-04-21
CY1122951T1 (el) 2021-10-29
IL298998B2 (en) 2024-07-01
LT3003284T (lt) 2020-04-27
RU2015151056A (ru) 2017-07-14
AU2014274890B2 (en) 2019-10-03
IL296484B2 (en) 2025-03-01
RS60464B1 (sr) 2020-07-31
EP3003284A1 (en) 2016-04-13
PL3003284T3 (pl) 2020-08-10
NZ714554A (en) 2021-06-25
CN110448537A (zh) 2019-11-15
CA2914049C (en) 2021-10-12
IL298998A (en) 2023-02-01
CA2914049A1 (en) 2014-12-11
PT3003284T (pt) 2020-08-10
IL242759B1 (en) 2023-01-01
JP6604941B2 (ja) 2019-11-13
KR102291860B1 (ko) 2021-08-20
US20190008846A1 (en) 2019-01-10
NZ754196A (en) 2021-06-25
EP3708154A1 (en) 2020-09-16
US10765672B2 (en) 2020-09-08
KR20220164069A (ko) 2022-12-12
HUE049623T2 (hu) 2020-09-28
IL298998B1 (en) 2024-03-01
AU2014274890A1 (en) 2015-12-17
MX2015016536A (es) 2016-08-11
JP2016523846A (ja) 2016-08-12
JP2019137703A (ja) 2019-08-22
MX2022011225A (es) 2022-10-07
RU2015151056A3 (https=) 2018-05-03
CN111728950A (zh) 2020-10-02

Similar Documents

Publication Publication Date Title
KR102291860B1 (ko) Hif 하이드록실라제 억제자의 약학적 제형
US20200297756A1 (en) Pharmaceutical formulations of nitrite and uses thereof
CN118806764A (zh) 缓释制剂及其使用方法
HK40032448A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
HK1222550B (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
NZ754196B2 (en) Pharmaceutical formulations of a HIF hydroxylase inhibitor
BR112015029693B1 (pt) Comprimido e cápsula compreendendo ácido [(4-hidróxi-1-metil-7-fenóxi-isoquinolina-3-carbonil)-amino]-acético
NZ714554B2 (en) Pharmaceutical formulations of a hif hydroxylase inhibitor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210813

Application number text: 1020157034392

Filing date: 20151202

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210910

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211222

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220625

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221124

Application number text: 1020157034392

Filing date: 20151202